Literature DB >> 18460969

Rotavirus.

Jim Gray1, Timo Vesikari, Pierre Van Damme, Carlo Giaquinto, Jacek Mrukowicz, Alfredo Guarino, Ron Dagan, Hania Szajewska, Vytautas Usonis.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18460969     DOI: 10.1097/MPG.0b013e31816f78ee

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  14 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  CD4+ CD25- FoxP3+ regulatory cells are the predominant responding regulatory T cells after human rotavirus infection or vaccination in gnotobiotic pigs.

Authors:  Ke Wen; Guohua Li; Xingdong Yang; Tammy Bui; Muqun Bai; Fangning Liu; Jacob Kocher; Lijuan Yuan
Journal:  Immunology       Date:  2012-10       Impact factor: 7.397

Review 3.  Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

Review 4.  Rotavirus vaccines and pathogenesis: 2008.

Authors:  Joseph M Hyser; Mary K Estes
Journal:  Curr Opin Gastroenterol       Date:  2009-01       Impact factor: 3.287

Review 5.  A critical literature review of health economic evaluations of rotavirus vaccination.

Authors:  Samuel Aballéa; Aurélie Millier; Sibilia Quilici; Stuart Caroll; Stavros Petrou; Mondher Toumi
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

6.  Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial.

Authors:  Andrew Duncan Steele; Kathleen M Neuzil; Nigel A Cunliffe; Shabir A Madhi; Pieter Bos; Bagrey Ngwira; Desiree Witte; Stacy Todd; Cheryl Louw; Mari Kirsten; Sanet Aspinall; Leen Jan Van Doorn; Alain Bouckenooghe; Pemmaraju V Suryakiran; Htay Htay Han
Journal:  BMC Infect Dis       Date:  2012-09-13       Impact factor: 3.090

7.  Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries.

Authors:  Greg L Plosker
Journal:  Drugs R D       Date:  2012-12-01

Review 8.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.558

Review 9.  Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.930

10.  Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model.

Authors:  Salem Alkoshi; Namaitijiang Maimaiti; Maznah Dahlui
Journal:  Libyan J Med       Date:  2014-12-09       Impact factor: 1.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.